US Stock MarketDetailed Quotes
TCRR TCR2 Therapeutics
- 1.480
- 0.0000.00%
Close Jun 2 09:30 ET
58.11MMarket Cap-352P/E (TTM)
0.000High0.000Low0Volume0.000Open1.480Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)39.26MShares2.04052wk High0.57P/B41.24MFloat Cap1.48052wk Low--Dividend TTM27.86MShs Float35.860Historical High--Div YieldTTM0.00%Amplitude0.821Historical Low--Avg Price1Lot Size
TCR2 Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | (Q3)Sep 30, 2021 | (Q2)Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -28.51%-40.01M | -24.33%-101.46M | -7.20%-24.96M | -33.32%-25.84M | -30.08%-19.53M | -30.12%-31.13M | -43.82%-81.6M | -72.46%-23.28M | -79.14%-19.38M | 6.22%-15.02M |
| Net income from continuing operations | -38.72%-40.4M | -52.12%-151.82M | -118.12%-60.51M | -16.58%-30.59M | -29.98%-31.6M | -35.38%-29.12M | -48.69%-99.81M | -50.34%-27.74M | -55.09%-26.24M | -49.66%-24.31M |
| Depreciation and amortization | -12.89%615K | 7.75%3.05M | -12.34%746K | 15.14%890K | 2.03%704K | 37.62%706K | 77.58%2.83M | 78.03%851K | 75.28%773K | 88.01%690K |
| Deferred tax | --0 | -395.96%-293K | --0 | --0 | -1,262.96%-314K | -41.67%21K | -24.43%99K | -113.33%-6K | -51.16%42K | --27K |
| Change In working capital | 33.91%-3.37M | 1,321.94%9.58M | 321.51%5.09M | -45.91%1.44M | 59.79%8.16M | 18.29%-5.11M | -189.91%-784K | -202.04%-2.3M | -28.12%2.65M | 359.42%5.11M |
| -Change in prepaid assets | 62.95%-1.63M | 322.64%5.56M | 219.71%2.94M | 233.85%1.5M | 210.93%5.52M | -94.26%-4.4M | -126.70%-2.5M | -417.18%-2.46M | -72.57%449K | 192.30%1.78M |
| -Change in payables and accrued expense | 162.13%671K | -67.47%1.34M | 907.59%1.91M | -43.69%901K | -113.33%-392K | -517.14%-1.08M | 109.22%4.13M | -116.05%-237K | -22.10%1.6M | 6,491.30%2.94M |
| -Change in other working capital | -744.00%-2.42M | 210.93%2.68M | -40.51%235K | -259.77%-965K | 672.26%3.04M | 109.85%375K | ---2.42M | --395K | --604K | --393K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -28.51%-40.01M | -24.33%-101.46M | -7.20%-24.96M | -33.32%-25.84M | -30.08%-19.53M | -30.12%-31.13M | -43.82%-81.6M | -72.46%-23.28M | -79.14%-19.38M | 6.22%-15.02M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 118.48%21.69M | -212.80%-88.49M | 121.78%3.66M | 8.57%35.56M | -122.76%-10.33M | -787.82%-117.37M | 260.31%78.45M | -388.42%-16.78M | 145.82%32.76M | 31.30%45.41M |
| Net PPE purchase and sale | 120.15%385K | -36.26%-15.12M | 63.82%-2.44M | -120.85%-4.79M | -763.20%-5.98M | -28.17%-1.91M | -54.91%-11.1M | -45.36%-6.75M | -67.54%-2.17M | 4.41%-693K |
| Net intangibles purchase and sale | --0 | 5.98%-330K | --0 | 80.56%-35K | -78.91%-229K | ---66K | ---351K | ---43K | ---180K | ---128K |
| Net investment purchase and sale | 118.46%21.3M | -181.24%-73.03M | 161.01%6.1M | 15.04%40.39M | -108.92%-4.12M | -721.90%-115.39M | 315.21%89.9M | -195.54%-9.99M | 150.00%35.1M | 30.93%46.23M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 118.48%21.69M | -212.80%-88.49M | 121.78%3.66M | 8.57%35.56M | -122.76%-10.33M | -787.82%-117.37M | 260.31%78.45M | -388.42%-16.78M | 145.82%32.76M | 31.30%45.41M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -59.32%24K | -99.91%125K | -68.70%41K | -79.01%72K | -138.52%-47K | -99.96%59K | -1.90%132.14M | -66.15%131K | -99.74%343K | 320.69%122K |
| Net common stock issuance | ---- | --0 | --0 | --0 | ---- | ---- | -1.68%131.33M | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | -70.43%34K | -78.96%256K | --0 | -73.90%113K | -86.27%28K | -69.41%115K | 2.35%1.22M | -54.36%204K | 0.23%433K | 63.20%204K |
| Net other financing activities | 82.14%-10K | 67.97%-131K | 156.16%41K | 54.44%-41K | 8.54%-75K | 65.85%-56K | -570.49%-409K | ---73K | ---90K | 14.58%-82K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -59.32%24K | -99.91%125K | -68.70%41K | -79.01%72K | -138.52%-47K | -99.96%59K | -1.90%132.14M | -66.15%131K | -99.74%343K | 320.69%122K |
| Net cash flow | ||||||||||
| Beginning cash position | -84.85%33.9M | 136.15%223.72M | -79.08%55.16M | -81.85%45.36M | -65.69%75.28M | 136.15%223.72M | 44.17%94.74M | 158.40%263.65M | 398.75%249.93M | 596.34%219.42M |
| Current changes in cash | 87.67%-18.3M | -247.17%-189.82M | 46.76%-21.26M | -28.60%9.8M | -198.02%-29.91M | -219.06%-148.45M | 344.38%128.98M | -447.54%-39.93M | -73.58%13.72M | 64.05%30.52M |
| End cash Position | -79.28%15.6M | -84.85%33.9M | -84.85%33.9M | -79.08%55.16M | -81.85%45.36M | -65.69%75.28M | 136.15%223.72M | 136.15%223.72M | 158.40%263.65M | 398.75%249.93M |
| Free cash flow | -21.31%-40.17M | -25.64%-116.91M | 8.88%-27.4M | -41.11%-30.66M | -62.55%-25.74M | -30.27%-33.11M | -45.61%-93.05M | -65.76%-30.07M | -79.39%-21.73M | 5.38%-15.84M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg